exhibits an antitumor effect not only against gastrointestinal cancer but also against various other cancers, including breast cancer and head and neck cancer [1] . Many methods of 5-FU administration have been explored, and protracted venous infusions of 5-FU led to higher response rates and less toxicity than bolus administration in colorectal cancer [2, 3] . 5-FU is currently widely used for the treatment of gastric cancer, and the clinical advantages of administration by continuous intravenous infusion have been reported [4] . However, infusional 5-FU requires intravenous infusion and infusion pumps. An attractive alternative method of delivering protracted 5-FU is through daily oral administration. Oral doses can be given on an ambulatory basis and are preferable from the viewpoint of patients' quality of life (QOL). S-1 is a novel oral fluoropyrimidine derivative based on a biochemical modulation of 5-FU. We reviewed basic and clinical data on S-1, which may be called the ultimate antineoplastic drug of the 5-FU series, with enhanced effects and reduced adverse reactions.
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Novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF): S-1

Mechanism of action and concept of S-1
S-1, a new oral antitumor agent, was designed based on the theory of biochemical modulation of 5-FU. In S-1, tegafur (FT) is combined with two classes of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), at a molar ratio of FT : CDHP : Oxo ϭ 1 : 0.4 : 1 [5] . The chemical structure of each ingredient is shown in Fig. 1 .
FT administered orally is absorbed stably in the small intestine, shows good bioavailability and sustained release, and is slowly converted to 5-FU in vivo, mainly by the liver microsomal P-450 drug-metabolizing enzyme Introduction 5-Fluorouracil (5-FU) is an antineoplastic drug that is effective against a wide spectrum of solid tumors; it [6] . However, approximately 80%-90% of 5-FU is degraded by liver DPD, converted to F--alanine, and excreted in urine [7] . The small remaining amount undergoes anabolism, and exhibits antitumor activity through such actions as the inhibition of thymidylate synthetase (TS) by fluorodeoxyuridine monophosphate (FdUMP), an active metabolite, and dysfunction of RNA by incorporation of fluorouridine triphosphate (FUTP) into RNA in tumor tissue. As is clear from the above, it is essential for the effective utilization of 5-FU to arrest the degradation of 5-FU and to increase fluoronucleotides in tumor cells. A series of studies of the substrates for DPD showed that uracil inhibited DPD to enhance the effect of FT. On the basis of this, the oral antitumor drug UFT (FT combined with uracil in a ratio of 1 : 4) was developed [8] . UFT was confirmed to show an antitumor effect against gastrointestinal and other solid tumors, and a number of clinical reports have been published concerning its effect on gastric cancer [9] . Recently, UFT was found in the West to show favorable results when used in combination with leucovorin in the treatment of advanced colorectaln cancer [10, 11] . Studies of DPD inhibition were conducted for the development of an ideal drug, which culminated in the discovery of CDHP. CDHP, a reversible competitive inhibitor of DPD, is a pyrimidine derivative with inhibitory activity approximately 180 times more potent than that of uracil, and a Ki of 3.6 ϫ 10 Ϫ7 M [12] (Fig. 2) . Thus, CDHP shows high affinity to DPD, and thereby 5-FU can be retained for longer at higher concentrations in the bloodstream by combining CDHP with FT [13] . Takechi et al. [14] demonstrated that CDHP inhibited 5-FU degradation and enhanced 5-FU cytotoxicity in human tumor cells in vitro, also suggesting that CDHP inhibits degradation of 5-FU in the tumor. At the same time, F--alanine, the main catabolite of 5-FU, is reduced, which leads to a reduction in toxicities such as neurotoxicity [15] . Sobrero et al. [16] proposed a new classification of fluoropyrimidines with DPD inhibitory activity as DPD inhibitory fluoropyrimidines (DIF), a group which includes UFT and S-1.
To reduce adverse reactions, it is considered necessary to reduce fluoronucleotides in the cells of the gastrointestinal mucosa and bone marrow. When Oxo was orally administered and its organ distribution was studied, it was found to be distributed at high concentrations in the small and large bowels, and was extremely scarce in the tumor. Thus, Oxo co-administered orally with 5-FU specifically inhibits the phosphorylation of 5-FU to fluoropyrimidine monophosphate (FUMP) catalyzed by orotate phosphoribosyl transferase (OPRT) within the gastrointestinal mucosal cells, and thereby reduces its gastrointestinal toxicity [17] . Furthermore, it was reported that Oxo, distributed in oral mucosa cells, modulated the occurrence of diarrhea and vomiting in dogs [18] . The optimal molar ratio of the three components of S-1 was defined using tumor-bearing rats as initial preclinical models [5] . In a nude rat system with several human tumor xenografts, S-1 exhibited excellent antitumor efficacy, and marked tumor shrinkage effects were observed in all five gastric tumors [19] . Accordingly, S-1 reduces neurotoxicity and gastrointestinal toxicity (diarrhea, nausea, and vomiting), and augments antitumor activity (Fig. 3) .
Clinical studies in gastric cancer
Phase I clinical trials
An initial phase I study of S-1 started in 1992 in Japan, and two administration methods, once and twice daily, were evaluated [20] .
In once-daily administration, pharmacokinetics and safety were investigated in dose escalation studies with 
5-FU
single doses of 25, 50, 100, 150, and 200 mg/body. Then, once-daily administration of the same doses was conducted for 28 days. The twice-daily administration regimen was carried out for 28 consecutive days with dose escalation from 50 mg to 75 mg and 100 mg/body twice daily. As a result, the maximum allowable dose (MAD) of S-1 was determined to be 50-200 mg/body per day in the once-a-day regimen and 75-100 mg/body in the twice-a-day regimen. Dose-limiting toxicity (DLT) was myelosuppression, mainly consisting of leucopenia, in the two regimens. Adverse reactions which caused discontinuation were rash and vomiting. Most of these adverse reactions resolved within 14 days after discontinuation. In the pharmacokinetic study, the blood concentration of 5-FU after a single administration of S-1 increased dose-dependently and was maintained at a high value for 12 h. Based on these findings, the recommended dosage and administration in early phase II studies were determined to be twice-daily administration of 75 mg/body for 28 consecutive days, with a 14-day washout period.
Phase II clinical trials
Early phase II studies of S-1 were conducted in patients with gastric, colorectal, breast, head and neck, and lung cancers [21] [22] [23] [24] [25] . S-1 was initially administered at 75 mg/ body twice daily for 28 days, followed by a 14-day washout period. However, because of rash, diarrhea, and severe myelosuppression, the dose of S-1 was reduced to 50 mg/body twice daily. Twenty-eight gastric cancer patients were evaluated. Nine of these patients had been treated previously with other anticancer drugs. Objective responses were seen in 15 of the 28 patients, with a response rate of 54%. Because 75 mg twice daily was associated with skin rash, severe myelosuppression and diarrhea, the actual dose given was calculated from the patient's body surface area (BSA). It was shown that the rate of discontinuation of administration due to such adverse reactions was markedly lower in patients given S-1 at 90 mg/m 2 Two pivotal late phase II studies of S-1 in advanced gastric cancer were conducted concurrently [26, 27] . The eligibility criteria of these trials were the same, as follows: measurable or evaluable gastric cancer with histological proof, performance status (PS) 0-2, age less than 75, no prior chemotherapy, adequate organ functions, and written informed consent. S-1 was administered orally twice daily after meals at a standard dose of 80 mg/m 2 per day. One course consisted of consecutive administration for 28 days and a 14-day washout period. Administration was repeated until disease progression or unacceptable toxicities. The response rates in these studies were 49% (25/51) and 40% (20/50), respectively. In a combined analysis of the two studies, the overall response rate was 44.6% (45/101) and the 95% confidence interval (CI) was 35.9%-62.3%. By site, the response rate was 33.8% (25/74) for primary lesions, 36.4% (16/44) for liver metastasis, 51.5% (34/66) for lymph node metastasis, and 16.7% (1/6) for lung metastasis. The median time to response was 35 days (range, 15-123 days) and the median total response period (from the start of administration to the onset of progression) was 158 days (range, 64-490 days). The median survival time (MST), 1-year survival rate, and 2-year survival rate were 244 days, 37%, and 17%, respectively (Fig. 4) . Toxicities were generally mild. Major toxicities over grade 3 were leucopenia (2%), neutropenia (5%), anemia (6%), and diarrhea (2%). S-1 appeared to be very well tolerated. Table 1 shows a summary of phase II studies of S-1 in gastric cancer. Table 2 shows the activity of approved single agents in advanced gastric cancer. The response rate for S-1 in 
Pharmacokinetics
A pharmacokinetic study of S-1 was conducted by Hirata et al. [35] to investigate 5-FU, FT, CDHP, and Oxo, after administration of S-1 at a standard dose of 80 mg/m 2 per day (40 mg/m 2 twice daily). In 28-day consecutive administration, the standard dose was given daily in two divided doses. Ten patients were evaluated. Pharmacokinetic parameters of plasma 5-FU were as follows: C max , 113.7 Ϯ 40.5 ng/ml; T max , 3.4 Ϯ 1.3 h; AUC 0-48 h , 609.0 Ϯ 170.2 ng · h/ml; and T 1/2 , 2.9 Ϯ 1.1 h. There were no fluctuations in pharmacokinetics and no drug accumulation with this schedule.
Yamada et al. [36] compared the pharmacokinetics of 5-FU and F--alanine in patients receiving protracted venous infusion (PVI) of 5-FU and oral S-1. Eight patients with gastric cancer received 5-FU at 250 mg/m 2 by PVI for 5 days (Lokich regimen), one of the standard administration schedules of 5-FU for gastrointestinal cancer. After a washout period of 9 days, S-1 was administered at 80 mg/m 2 (40 mg/m 2 twice daily) for 28 days. Plasma concentrations of 5-FU and F--alanine were measured in the same patients. The C max of 5-FU was 94.5 Ϯ 19.5 ng/ml for PVI 5-FU and 209.1 Ϯ 56.2 ng/ml for S-1, and the AUC 0-10 h of 5-FU was 731.6 Ϯ 161.7 ng · h/ml for PVI 5-FU and 1244.6 Ϯ 262.4 ng · h/ml for S-1. The AUC 0-10 h of F--alanine was 8441.7 Ϯ 2825.7 ng · h/ml for PVI 5-FU and 1458.3 Ϯ 573.8 ng h/ml for S-1. Thus, although the C max and AUC of 5-FU values were higher for S-1 than for PVI 5-FU, the plasma concentration of F--alanine, the main metabolite of 5-FU, was significantly higher for PVI 5-FU than for S-1.
Combination clinical trials
Ohtsu et al. [37] reported the results of a combination phase I/II study of S-1 plus cisplatin (CDDP) in gastric cancer. S-1 was administered orally at 80 mg/m 2 per day (40 mg/m 2 twice daily) for 21 consecutive days, and CDDP was infused over 2 h (levels 1, 2, and 3; 60, 70, and 80 mg/m 2 ) on day 8. This schedule was repeated every 4-5 weeks. A total of 25 patients who had no previous chemotherapy, 12 for phase I and 13 additional patients for phase II, were registered. Level 2 (70 mg/m 2 of CDDP) was determined as the maximum tolerated dose (MTD) and the dose at level 1 (60 mg/m 2 of CDDP) was used for the subsequent trial. Objective responses were seen in 19 of the 25 patients, with a response rate of 76%. A phase III study is ongoing to evaluate the survival benefit of this combination therapy in gastric cancer. CR, complete response; PR, partial response; UFT, Tegafur ϩ uracil (molar ratio 1 : 4); 5ЈDFUR, 5Ј-deoxy-5-fluorouridine; CDDP, cisplatin; CPT-II, irinotecan
Combination phase I studies of S-1 plus irinotecan (CPT-11) in gastric cancer were conducted. Narahara et al. [38] reported a phase I study of S-1 plus biweekly CPT-11 in gastric cancer. S-1 was administered orally at 80 mg/m 2 per day for 21 consecutive days, and CPT-11 was infused over 90 min (levels 1, 2, 3, 4, and 5; 40, 60, 80, 100, and 120 mg/m 2 ) on day 1 and day 15. Nineteen patients were registered in this study. Level 4 (100 mg/ m 2 of CPT-11) was determined as the MTD and the recommended dose of CPT-11 was determined to be 80 mg/m 2 (level 3). The overall response rate was 56% (10/18). Komatsu et al.
[39] reported a study in which S-1 was administered orally at 80 mg/m 2 per day (40 mg/m 2 twice a day) for 14 consecutive days, and CPT-11 was infused over 90 min (levels 1, 2, and 3; 100, 125, and 150 mg/m 2 ) on day 1 and day 15. This schedule was repeated every 4 weeks. Fifteen patients were registered in this study. The recommended dose for this combination was determined to be CPT-11 125 mg/m 2 (level 2). The overall response rate was 53% (8/15) . Phase II studies have already started in both study groups.
Postmarketing survey and clinical practice
Manufacturing approval for S-1 was granted in January 1999. The postmarketing surveillance was conducted for 1 year, with a target population of 3000 cases, and the tolerability and safety of S-1 for gastric cancer were evaluated. In the interim analysis of the postmarketing survey in Japan, the tolerability and the safety profile of S-1 were assessed in 3294 patients with gastric cancer [40] . S-1 was basically administered at a standard dose of 80 mg/m 2 per day (40 mg/m 2 twice daily after meals) on 28 consecutive days, followed by a 14-day washout period. The number of cycles actually administered was as follows: two or more courses, 72% (2372/3294) and three or more courses, 47% (1534/3294). In these surveys, the overall incidence of adverse reactions was 74% (2441 of 3294 patients). Frequent adverse events in the late phase II study and postmarketing surveillance are listed in Table 3 . Major adverse events and their frequencies were similar in the above two studies, and the most common toxicity was hematological toxicities such as leucopenia. Multivariate analysis revealed that grade 3 or worse hematological toxicities occurred significantly more frequently in patients with impairment of renal function. Ikeda et al. [41] investigated the pharmacokinetics of S-1 in an experimental renalfailure animal model and in patients with impaired renal function. There were higher and longer-lasting 5-FU concentrations, and subsequent values for AUC increased, in the experimental renal-failure model and in patients with renal impairment, due to the retention of CDHP. These findings demonstrated that the administration of S-1 to patients with impaired renal function might require individualized dosing and pharmacokinetic monitoring.
Many reports are available on the utility of S-1 in clinical practice, and, as well, there are case reports concerning S-1 used in patients with gastric cancer at various evaluable sites [42] [43] [44] [45] [46] [47] [48] ; these studies testify to the utility of S-1 in medical practice.
Future perspectives
The response rate for S-1 in gastric cancer is over 40% (which exceeds the response rates for other approved drugs that remain at around 20%), and is comparable to the previously reported response rates for representative combination chemotherapies such as fluorouracil plus CDDP regimens [49] [50] [51] . These data suggest that S-1 can be used as a first-line drug in chemotherapy for gastric cancer. Moreover, S-1 administered orally has a great advantage in that it can be used on an ambulatory basis to improve the QOL of patients. Although it is necessary to verify the life-prolonging effect of S-1 in a On the basis of this review of basic and clinical studies to date, S-1 is believed to be the ultimate fluoropyrimidine, based on the biochemical modulation of 5-FU. S-1 is currently considered to be the first candidate as the standard drug for gastric cancer and should be used as first-line chemotherapy. Through the accumulation of evidence from ongoing and future clinical trials, it is certain that chemotherapy including S-1 will become state-of-the-art treatment for gastric cancer in future.
